- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Soliman on the Use of ctDNA as a Clinical Trial End Point in Endometrial Cancer
March 28th 2023, 9:55pm
Pamela T. Soliman, MD, MPH, discusses the use of circulating tumor DNA a clinical trial end point in endometrial cancer.
Neoadjuvant Olaparib Proves Feasible, Aids Optimal Resection in BRCA-Mutant Ovarian Cancer
March 28th 2023, 7:50pm
Neoadjuvant treatment with olaparib prior to surgical resection and adjuvant chemotherapy was well tolerated and led to a 100% optimal resection rate in patients with newly diagnosed, BRCA-mutant ovarian, primary peritoneal, or fallopian tube cancer.
Dr Berkenstock on the Mitigation of ADC-related Ocular Toxicities in Gynecologic Cancers
March 28th 2023, 7:29pm
Meghan K. Berkenstock, MD, discusses the management of antibody-drug conjugate-related ocular toxicities in gynecologic cancers.
Dr Eskander on Pembrolizumab Plus Paclitaxel and Carboplatin in Endometrial Cancer
March 28th 2023, 6:15pm
Ramez N. Eskander, MD, discusses findings from the phase 3 NRG GY018 trial of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer
March 28th 2023, 6:02pm
Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial Cancer
March 28th 2023, 4:39pm
Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.
Dr Bockorny on Botensilimab Plus Balstilimab in Ovarian Cancer
March 28th 2023, 3:30pm
Bruno B. Bockorny, MD, discusses findings from a phase 1a/b trial with the combination of botensilimab and balstilimab in patients with recurrent platinum-refractory or platinum-resistant ovarian cancer.
Dr Mirza on Dostarlimab Plus Chemotherapy in Endometrial Cancer
March 28th 2023, 2:15am
Mansoor Raza Mirza, MD, discusses findings from the phase 3 RUBY trial in patients with endometrial cancer.
Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer
March 27th 2023, 8:57pm
Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.
Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection
March 27th 2023, 8:51pm
Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.
Botensilimab/Balstilimab Combo Elicits Deep Responses in Platinum-Resistant/Refractory Ovarian Cancer
March 27th 2023, 8:09pm
Botensilimab in combination with balstilimab induced durable responses in patients with resistant/refractory ovarian cancer.
Lenvatinib Plus Pembrolizumab Produces Deep, Sustained Responses in Advanced Endometrial Cancer
March 27th 2023, 7:59pm
The combination of lenvatinib plus pembrolizumab produced deep, durable tumor responses in both all-comer and mismatch repair–proficient (pMRR) populations of patients with advanced endometrial cancer, according to data from the phase 3 Study 309/KEYNOTE-775 trial.
Toripalimab Plus Bevacizumab/Chemotherapy Generates Responses in Refractory, Recurrent, or Metastatic Cervical Cancer
March 27th 2023, 6:42pm
The combination of toripalimab, bevacizumab, and platinum-based chemotherapy elicited responses in patients with refractory, recurrent or metastatic cervical cancer.
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer
March 27th 2023, 6:41pm
Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
Tolerability Hinders Adavosertib Activity in Recurrent or Persistent Uterine Serous Carcinoma
March 27th 2023, 6:34pm
Treatment with the oral, small-molecule Wee1 kinase inhibitor adavosertib was clinically active but not well tolerated in patients with recurrent or persistent uterine serous carcinoma who previously received platinum-based chemotherapy.
Durvalumab Plus Tremelimumab and Hypofractionated Radiotherapy Shows Early Promise in Gynecologic Cancers
March 27th 2023, 6:26pm
The combination of durvalumab, tremelimumab, and hypofractionated radiotherapy demonstrated early tolerability in patients with gynecologic malignancies and elicited objective responses in those with PD-L1–high tumors.
Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer
March 27th 2023, 5:55pm
Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.
Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer
March 27th 2023, 4:45pm
Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.
Carolina Frailty Index Score Shows Utility in Ovarian Cancer Setting
March 27th 2023, 4:39pm
Women with ovarian cancer may be effectively assessed for frailty status via the Carolina Frailty Index Score.
Olaparib Plus Selumetinib Produces Clinical Benefit in RAS-Mutated Ovarian and Endometrial Cancer
March 27th 2023, 4:03pm
The recommended phase 2 dose of olaparib plus selumetinib generated a clinical benefit in patients with endometrial or ovarian cancer harboring RAS mutations, according to findings from the dose-expansion portion of the phase 1b SOLAR trial.